ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? Study protocol for a randomized, double-blind, and placebo-controlled trial

Ruan, Guangfeng; Yuan, Shiwen; Lou, Aiju; Mo, Yingqian; Qu, Yuan; Guo, Dongmei; Guan, Shangqi; Zhang, Yan; Lan, Xiaoyong; Luo, Jun; Mei, Yifang; Zhang, Hongwei; Wu, Weirong; Dai, Lie; Yu, Qinghong; Cai, Xiaoyan*; Ding, Changhai*佛山市第一人民医院; 南昌大学; 南方医科大学; 中山大学; 1
BMC MUSCULOSKELETAL DISORDERS2022-5-21DOI: 10.1186/s12891-022-05434-2
4被引15阅读
引用收藏
分享

摘要

Background: Osteoarthritis (OA) is the most common joint disease, and is most frequently seen in the knees. However, there is no effective therapy to relieve the progression of knee OA. Metformin is a safe, well-tolerated oral medication that is extensively used as first-line therapy for type 2 diabetes. Previous observational studies and basic researches suggested that metformin may have protective effects on knee OA, which needs to be verified by clinical trials. This study, therefore, aims to examine the effects of metformin versus placebo on knee cartilage volume loss and knee symptoms in overweight knee OA patients by a randomized controlled trial over 24 months. @@@ Methods: This protocol describes a multicenter, randomized, double-blind, and placebo-controlled clinical trial aiming to recruit 262 overweight knee OA patients. Participants will be randomly allocated to the two arms of the study, receiving metformin hydrochloride sustained-release tablets or identical inert placebo for 24 months (start from 0.5 g/day for the first 2 weeks, and increase to 1 g/day for the second 2 weeks, and further increase to 2 g/day for the remaining period if tolerated). Primary outcomes will be changes in tibiofemoral cartilage volume and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score over 24 months. Secondary outcomes will be changes in visual analogue scale (VAS) knee pain, tibiofemoral cartilage defects, effusion-synovitis volume, and tibiofemoral bone marrow lesions maximum size over 24 months. The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per-protocol analyses will be performed as the secondary analyses. @@@ Discussion: If metformin is proved to slow knee cartilage volume loss and to relieve knee symptoms among overweight knee OA patients, it will have the potential to become a disease modifying drug for knee OA. Metformin is a convenient intervention with low cost, and its potential effects on slowing down the structural progression and relieving the symptoms of knee OA would effectively reduce the disease burden worldwide.

学科与关键词

关键词
Knee osteoarthritisMetforminRandomized controlled trial
相关
加载中…
  • Association between Metformin Use and Risk of Total Knee Arthroplasty and Degree of Knee Pain in Knee Osteoarthritis Patients with Diabetes and/or Obesity: A Retrospective Study
    Chen, Shibo; Ruan, Guangfeng; Zeng, Muhui; Chen, Tianyu; Cao, Peihua; Zhang, Yan; Li, Jia; Wang, Xiaoshuai; Li, Shengfa; Tang, Su'an; Lu, Shilong; Fan, Tianxiang; Li, Yang; Han, Weiyu; Tan, Jianye; Ding, Changhai*; Zhu, Zhaohua*Journal of Clinical Medicine, 2022, 11(16): 4796.被引 5
  • Metformin attenuates osteoarthritis by targeting chondrocytes, synovial macrophages and adipocytes
    Li, Delong; Ruan, Guangfeng; Zhang, Yan; Zhao, Yang; Zhu, Zhaohua; Ou, Qianhua; Huang, Hong; Chen, Jieli; Han, Weiyu; Tang, Su'an; Li, Jia; Wang, Liang; Chen, Tianyu; Bai, Xiaochun; Cai, Daozhang; Ding, Changhai*RHEUMATOLOGY, 2023, 62(4): 1652-1661.被引 9
  • Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial
    Wang, Yuanyuan; Jones, Graeme; Hill, Catherine; Wluka, Anita E.; Forbes, Andrew B.; Tonkin, Andrew; Hussain, Sultana Monira; Ding, Changhai; Cicuttini, Flavia M.*Arthritis & Rheumatology, 2021, 73(11): 2035-2043.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC MUSCULOSKELETAL DISORDERS
发表日期
2022-05-21
卷期
第 23 卷, 第 1 期
页码
486
DOI
10.1186/s12891-022-05434-2
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Guangdong Basic and Applied Basic Research Foundation [2019A1515110620]

作者

  • R

    Ruan, Guangfeng (第一作者)

    1 · southern med univ

  • Y

    Yuan, Shiwen

    1

查看全部 17 位作者收起作者
  • L

    Lou, Aiju

  • M

    Mo, Yingqian

    sun yat sen univ

  • Q

    Qu, Yuan

    southern med univ

  • G

    Guo, Dongmei

    foshan first peoples hosp

  • G

    Guan, Shangqi

    2

  • Z

    Zhang, Yan

    southern med univ

  • L

    Lan, Xiaoyong

    2 · nanchang univ

  • L

    Luo, Jun

    2 · nanchang univ

  • M

    Mei, Yifang

    2

  • Z

    Zhang, Hongwei

    foshan first peoples hosp

  • W

    Wu, Weirong

  • D

    Dai, Lie

    sun yat sen univ

  • Y

    Yu, Qinghong

    southern med univ

  • C

    Cai, Xiaoyan (通讯)

    1

  • D

    Ding, Changhai (通讯)

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417